Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling

Martina Rauner, Ulrike Baschant, Antonella Roetto, Rosa Maria Pellegrino, Sandra Rother, Juliane Salbach-Hirsch, Heike Weidner, Vera Hintze, Graeme Campbell, Andreas Petzold, Regis Lemaitre, Ian Henry, Teresita Bellido, Igor Theurl, Sandro Altamura, Silvia Colucci, Martina U. Muckenthaler, Georg Schett, Davide S.K. Komla-Ebri, J. H.Duncan BassettGraham R. Williams, Uwe Platzbecker, Lorenz C. Hofbauer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Transferrin receptor 2 (Tfr2) is mainly expressed in the liver and controls iron homeostasis. Here, we identify Tfr2 as a regulator of bone homeostasis that inhibits bone formation. Mice lacking Tfr2 display increased bone mass and mineralization independent of iron homeostasis and hepatic Tfr2. Bone marrow transplantation experiments and studies of cell-specific Tfr2-knockout mice demonstrate that Tfr2 impairs BMP-p38MAPK signalling and decreases expression of the Wnt inhibitor sclerostin, specifically in osteoblasts. Reactivation of MAPK or overexpression of sclerostin rescues skeletal abnormalities in Tfr2-knockout mice. We further show that the extracellular domain of Tfr2 binds bone morphogenic proteins (BMPs) and inhibits BMP-2-induced heterotopic ossification by acting as a decoy receptor. These data indicate that Tfr2 limits bone formation by modulating BMP signalling, possibly through direct interaction with BMP either as a receptor or as a co-receptor in complex with other BMP receptors. Finally, the Tfr2 extracellular domain may be effective in the treatment of conditions associated with pathological bone formation.

Original languageEnglish (US)
Pages (from-to)111-124
Number of pages14
JournalNature Metabolism
Volume1
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Wnt Proteins
Transferrin Receptors
Osteogenesis
Bone and Bones
Proteins
Homeostasis
Knockout Mice
Iron
Heterotopic Ossification
Physiologic Calcification
Liver
Osteoblasts
Bone Marrow Transplantation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)
  • Internal Medicine
  • Cell Biology

Cite this

Rauner, M., Baschant, U., Roetto, A., Pellegrino, R. M., Rother, S., Salbach-Hirsch, J., ... Hofbauer, L. C. (2019). Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling. Nature Metabolism, 1(1), 111-124. https://doi.org/10.1038/s42255-018-0005-8

Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling. / Rauner, Martina; Baschant, Ulrike; Roetto, Antonella; Pellegrino, Rosa Maria; Rother, Sandra; Salbach-Hirsch, Juliane; Weidner, Heike; Hintze, Vera; Campbell, Graeme; Petzold, Andreas; Lemaitre, Regis; Henry, Ian; Bellido, Teresita; Theurl, Igor; Altamura, Sandro; Colucci, Silvia; Muckenthaler, Martina U.; Schett, Georg; Komla-Ebri, Davide S.K.; Bassett, J. H.Duncan; Williams, Graham R.; Platzbecker, Uwe; Hofbauer, Lorenz C.

In: Nature Metabolism, Vol. 1, No. 1, 01.01.2019, p. 111-124.

Research output: Contribution to journalArticle

Rauner, M, Baschant, U, Roetto, A, Pellegrino, RM, Rother, S, Salbach-Hirsch, J, Weidner, H, Hintze, V, Campbell, G, Petzold, A, Lemaitre, R, Henry, I, Bellido, T, Theurl, I, Altamura, S, Colucci, S, Muckenthaler, MU, Schett, G, Komla-Ebri, DSK, Bassett, JHD, Williams, GR, Platzbecker, U & Hofbauer, LC 2019, 'Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling', Nature Metabolism, vol. 1, no. 1, pp. 111-124. https://doi.org/10.1038/s42255-018-0005-8
Rauner M, Baschant U, Roetto A, Pellegrino RM, Rother S, Salbach-Hirsch J et al. Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling. Nature Metabolism. 2019 Jan 1;1(1):111-124. https://doi.org/10.1038/s42255-018-0005-8
Rauner, Martina ; Baschant, Ulrike ; Roetto, Antonella ; Pellegrino, Rosa Maria ; Rother, Sandra ; Salbach-Hirsch, Juliane ; Weidner, Heike ; Hintze, Vera ; Campbell, Graeme ; Petzold, Andreas ; Lemaitre, Regis ; Henry, Ian ; Bellido, Teresita ; Theurl, Igor ; Altamura, Sandro ; Colucci, Silvia ; Muckenthaler, Martina U. ; Schett, Georg ; Komla-Ebri, Davide S.K. ; Bassett, J. H.Duncan ; Williams, Graham R. ; Platzbecker, Uwe ; Hofbauer, Lorenz C. / Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling. In: Nature Metabolism. 2019 ; Vol. 1, No. 1. pp. 111-124.
@article{2521ed71242642edb6a85f62f3679ff0,
title = "Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling",
abstract = "Transferrin receptor 2 (Tfr2) is mainly expressed in the liver and controls iron homeostasis. Here, we identify Tfr2 as a regulator of bone homeostasis that inhibits bone formation. Mice lacking Tfr2 display increased bone mass and mineralization independent of iron homeostasis and hepatic Tfr2. Bone marrow transplantation experiments and studies of cell-specific Tfr2-knockout mice demonstrate that Tfr2 impairs BMP-p38MAPK signalling and decreases expression of the Wnt inhibitor sclerostin, specifically in osteoblasts. Reactivation of MAPK or overexpression of sclerostin rescues skeletal abnormalities in Tfr2-knockout mice. We further show that the extracellular domain of Tfr2 binds bone morphogenic proteins (BMPs) and inhibits BMP-2-induced heterotopic ossification by acting as a decoy receptor. These data indicate that Tfr2 limits bone formation by modulating BMP signalling, possibly through direct interaction with BMP either as a receptor or as a co-receptor in complex with other BMP receptors. Finally, the Tfr2 extracellular domain may be effective in the treatment of conditions associated with pathological bone formation.",
author = "Martina Rauner and Ulrike Baschant and Antonella Roetto and Pellegrino, {Rosa Maria} and Sandra Rother and Juliane Salbach-Hirsch and Heike Weidner and Vera Hintze and Graeme Campbell and Andreas Petzold and Regis Lemaitre and Ian Henry and Teresita Bellido and Igor Theurl and Sandro Altamura and Silvia Colucci and Muckenthaler, {Martina U.} and Georg Schett and Komla-Ebri, {Davide S.K.} and Bassett, {J. H.Duncan} and Williams, {Graham R.} and Uwe Platzbecker and Hofbauer, {Lorenz C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s42255-018-0005-8",
language = "English (US)",
volume = "1",
pages = "111--124",
journal = "Nature Metabolism",
issn = "2522-5812",
number = "1",

}

TY - JOUR

T1 - Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling

AU - Rauner, Martina

AU - Baschant, Ulrike

AU - Roetto, Antonella

AU - Pellegrino, Rosa Maria

AU - Rother, Sandra

AU - Salbach-Hirsch, Juliane

AU - Weidner, Heike

AU - Hintze, Vera

AU - Campbell, Graeme

AU - Petzold, Andreas

AU - Lemaitre, Regis

AU - Henry, Ian

AU - Bellido, Teresita

AU - Theurl, Igor

AU - Altamura, Sandro

AU - Colucci, Silvia

AU - Muckenthaler, Martina U.

AU - Schett, Georg

AU - Komla-Ebri, Davide S.K.

AU - Bassett, J. H.Duncan

AU - Williams, Graham R.

AU - Platzbecker, Uwe

AU - Hofbauer, Lorenz C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Transferrin receptor 2 (Tfr2) is mainly expressed in the liver and controls iron homeostasis. Here, we identify Tfr2 as a regulator of bone homeostasis that inhibits bone formation. Mice lacking Tfr2 display increased bone mass and mineralization independent of iron homeostasis and hepatic Tfr2. Bone marrow transplantation experiments and studies of cell-specific Tfr2-knockout mice demonstrate that Tfr2 impairs BMP-p38MAPK signalling and decreases expression of the Wnt inhibitor sclerostin, specifically in osteoblasts. Reactivation of MAPK or overexpression of sclerostin rescues skeletal abnormalities in Tfr2-knockout mice. We further show that the extracellular domain of Tfr2 binds bone morphogenic proteins (BMPs) and inhibits BMP-2-induced heterotopic ossification by acting as a decoy receptor. These data indicate that Tfr2 limits bone formation by modulating BMP signalling, possibly through direct interaction with BMP either as a receptor or as a co-receptor in complex with other BMP receptors. Finally, the Tfr2 extracellular domain may be effective in the treatment of conditions associated with pathological bone formation.

AB - Transferrin receptor 2 (Tfr2) is mainly expressed in the liver and controls iron homeostasis. Here, we identify Tfr2 as a regulator of bone homeostasis that inhibits bone formation. Mice lacking Tfr2 display increased bone mass and mineralization independent of iron homeostasis and hepatic Tfr2. Bone marrow transplantation experiments and studies of cell-specific Tfr2-knockout mice demonstrate that Tfr2 impairs BMP-p38MAPK signalling and decreases expression of the Wnt inhibitor sclerostin, specifically in osteoblasts. Reactivation of MAPK or overexpression of sclerostin rescues skeletal abnormalities in Tfr2-knockout mice. We further show that the extracellular domain of Tfr2 binds bone morphogenic proteins (BMPs) and inhibits BMP-2-induced heterotopic ossification by acting as a decoy receptor. These data indicate that Tfr2 limits bone formation by modulating BMP signalling, possibly through direct interaction with BMP either as a receptor or as a co-receptor in complex with other BMP receptors. Finally, the Tfr2 extracellular domain may be effective in the treatment of conditions associated with pathological bone formation.

UR - http://www.scopus.com/inward/record.url?scp=85064080845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064080845&partnerID=8YFLogxK

U2 - 10.1038/s42255-018-0005-8

DO - 10.1038/s42255-018-0005-8

M3 - Article

AN - SCOPUS:85064080845

VL - 1

SP - 111

EP - 124

JO - Nature Metabolism

JF - Nature Metabolism

SN - 2522-5812

IS - 1

ER -